A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...
The Motley Fool on MSN9h
Is Viking Therapeutics a Buy on the Dip?Eli Lilly is studying two weight loss candidates in phase 3 trials ... A small player like Viking may also win by attracting ...
Eli Lilly (NYSE:LLY) shares were on track to snap six straight sessions of losses on Thursday, as the stock rose 1.9% at $790 ...
2don MSN
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...
We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...
In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...
Despite the above, there are still a couple of silver linings that provide more than enough reason to be bullish about this stock.
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...
Nvidia's stock market value ended the day at $3.65 trillion, beating Apple's record closing market capitalization of $3.57 ...
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback